Advanced Cancer, Glioblastoma, High Grade Glioma, Melanoma, Recurrent Glioblastoma
Conditions
Brief summary
Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
Detailed description
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Interventions
DRUGGX-I7
patients will receive the assigned dose of GX-I7 intramuscular injection every 4\ 12 weeks
Sponsors
Genexine, Inc.
Eligibility
Inclusion criteria
\-
Exclusion criteria
\-
Countries
South Korea
Outcome results
None listed